CSL Ltd (CSL.AX)
21 Jul 2017
* has become aware that Bioverativ has filed complaints in U.S. District Court for district of Delaware
July 3 Australian shares extended losses from the end of last week, with Monday's weakness led by biotech giant CSL Ltd, the biggest drag on the benchmark, while Fairfax Media tumbled after two private equity firms withdrew rival takeover bids.
BRIEF-CSL to acquire majority stake in chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products
* CSL to acquire majority stake in chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products Source text for Eikon: Further company coverage:
May 24 Australian shares pared early gains to end marginally higher on Wednesday, underpinned by industrial and consumer stocks.
* Momenta Pharmaceuticals announces Hart-Scott-Rodino clearance for collaboration and license agreement with CSL
* "Group's net profit after tax (NPAT) is expected to grow in range of approximately 18 to 20% at constant currency"